NEW YORK, May 31, 2017 /PRNewswire/ --
Pre-market, Stock-Callers.com has issued research reports on Agilent Technologies
On Tuesday, shares in Santa Clara, California headquartered Agilent Technologies Inc. rose 1.45%, ending the day at $60.37. The stock recorded a trading volume of 2.58 million shares, which was above its three months average volume of 1.90 million shares. The Company's shares have advanced 9.66% in the last one month, 17.68% over the previous three months, and 32.51% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 10.28% and 22.90%, respectively. Moreover, shares of Agilent Technologies, which provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, have a Relative Strength Index (RSI) of 78.94.
On May 17th, 2017, Agilent Technologies announced that a quarterly dividend of 13.2 cents per share of common stock will be paid on July 26th, 2017, to all shareholders of record as of the close of business on July 03rd, 2017. The timing and amounts of future dividends are subject to determination and approval by the Company's board. A complete research report is just a click away and free at:
Shares in Waltham, Massachusetts headquartered Alere Inc. ended the day 0.33% lower at $48.66 with a total trading volume of 555,052 shares. In the previous three months and on an YTD basis, the stock has gained 27.05% and 24.87%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 7.35% and 17.32%, respectively. Furthermore, shares of Alere, which provides professional diagnostic products and services for infectious and cardiometabolic disease, and toxicology in the US, Europe, and internationally, have an RSI of 64.04.
On May 22nd, 2017, Alere announced certain preliminary unaudited financial information for Q4 ended December 31st, 2016, and Q1 2017 ended March 31st, 2017. For Q4 2016, total revenue is expected to be $597 million, and non-GAAP organic growth is expected to be -0.9%, or +3.7%, excluding Arriva. For Q1 2017, total revenue is expected to be $588 million, and non-GAAP organic growth is expected to be +0.9%, or +6.8%, excluding Arriva. The complimentary report on ALR can be downloaded at:
At the close of trading on Tuesday, shares in Durham, North Carolina headquartered Quintiles IMS Holdings Inc. finished 0.60% lower at $85.50 with a total trading volume of 884,026 shares. The stock has advanced 1.45% in the last one month, 10.48% over the previous three months, and 12.43% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 4.85% and 9.20%, respectively. Additionally, shares of Quintiles IMS, which provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and Asia/Pacific, have an RSI of 63.08.
On May 03rd, 2017, Quintiles IMS reported financial results for the quarter ended March 31st, 2017. Revenue for Q1 2017 was $1,911 million, adjusted EBITDA was $467 million, GAAP net income was $74 million, and GAAP diluted earnings per share (EPS) was $0.31. Adjusted net income for the quarter was $238 million, and adjusted diluted EPS was $1.01.
On May 04th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $90 a share to $93 a share. Sign up for your complimentary research report on Q at:
Thermo Fisher Scientific
Waltham, Massachusetts headquartered Thermo Fisher Scientific Inc.'s shares recorded a trading volume of 1.11 million shares at the end of yesterday's session. The stock closed the day 0.10% lower at $173.25. The Company's shares have advanced 4.79% in the past month, 9.87% in the previous three months, and 22.79% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.07% and 13.02%, respectively. Additionally, shares of Thermo Fisher Scientific, which provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide, have an RSI of 72.66.
On May 18th, 2017, the Company announced that its board of directors declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on July 17th, 2017, to shareholders of record as of June 15th, 2017. Get free access to your research report on TMO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...View All